Virodhamine (CAS 287937-12-6)
QUICK LINKS
Virodhamine is a compound that has attracted interest within the research community due to its classification as an endocannabinoid. Virodhamine is particularly noteworthy for its simultaneous agonist activity at the CB2 receptor and antagonist activity at the CB1 receptor, distinguishing it from other endocannabinoids. This dual activity makes it a subject of interest in the study of signal transduction pathways and their implications for cellular communication. Research involving virodhamine also extends to the exploration of lipid signaling pathways, as it contributes to the understanding of how lipid-based signaling molecules are synthesized, released, and degraded. The compound′s unique interactions with cannabinoid receptors are also studied to elucidate the complex dynamics of receptor activation and inhibition, which has broader implications for the field of neurobiology and the study of homeostatic regulation.
Virodhamine (CAS 287937-12-6) References
- Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. | Porter, AC., et al. 2002. J Pharmacol Exp Ther. 301: 1020-4. PMID: 12023533
- Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. | Ho, WS. and Hiley, CR. 2004. J Pharm Pharmacol. 56: 869-75. PMID: 15233865
- Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. | Steffens, M., et al. 2005. Biochem Pharmacol. 69: 169-78. PMID: 15588725
- Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. | Gkoumassi, E., et al. 2007. Br J Pharmacol. 151: 1041-8. PMID: 17558435
- GPR55: a new member of the cannabinoid receptor clan? | Pertwee, RG. 2007. Br J Pharmacol. 152: 984-6. PMID: 17876300
- The orphan receptor GPR55 is a novel cannabinoid receptor. | Ryberg, E., et al. 2007. Br J Pharmacol. 152: 1092-101. PMID: 17876302
- Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. | Kozłowska, H., et al. 2008. Br J Pharmacol. 155: 1034-42. PMID: 18806815
- (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. | Gkoumassi, E., et al. 2009. Naunyn Schmiedebergs Arch Pharmacol. 380: 67-77. PMID: 19255745
- Role of endocannabinoids in cardiovascular shock. | Malinowska, B., et al. 2008. J Physiol Pharmacol. 59 Suppl 8: 91-107. PMID: 19258666
- [Endogenous cannabinoids in liver disease: Many darts for a single target]. | Reichenbach, V., et al. 2010. Gastroenterol Hepatol. 33: 323-9. PMID: 19758727
- The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. | Sharir, H., et al. 2012. J Neuroimmune Pharmacol. 7: 856-65. PMID: 22454039
- Mechanism of platelet activation induced by endocannabinoids in blood and plasma. | Brantl, SA., et al. 2014. Platelets. 25: 151-61. PMID: 23789792
- Activation of platelets by the endocannabinoids 2-arachidonoylglycerol and virodhamine is mediated by their conversion to arachidonic acid and thromboxane A2, not by activation of cannabinoid receptors. | Brantl, SA., et al. 2014. Platelets. 25: 465-6. PMID: 24102401
- Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. | Pandey, P., et al. 2018. Biochem Pharmacol. 155: 82-91. PMID: 29958841
- Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. | Sharma, DS., et al. 2021. J Cell Physiol. 236: 1445-1453. PMID: 32696508
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Virodhamine, 5 mg | sc-204383 | 5 mg | $312.00 | |||
Virodhamine, 25 mg | sc-204383A | 25 mg | $1040.00 |